About: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 1992

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 1992 (uk) im Januar 1992 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 1992 (ast) ശാസ്ത്രപ്രബന്ധം (ml) artikull shkencor i botuar më 01 janar 1992 (sq) scientific article published on 01 January 1992 (en)
publication date	wds:Q67879264-6FB3CFE9-5CFB-4B0A-BB30-4CF77880A10D
publication date	1992-01-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q67879264-B1200678-B359-4C18-9958-0AD61FCFB3A4
language of work or name	English
rdfs:label	Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (en) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (nl) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (sq)
skos:prefLabel	Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (en) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (nl) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (sq)
name	Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (en) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (nl) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (sq)
title	wds:Q67879264-EB2A61E8-4CC1-4C93-B4FB-97D639012D22
title	Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group (en)
page(s)	wds:Q67879264-13B20C93-70A8-4066-BA07-939B34A6ADD9
page(s)	71-85
instance of	wds:Q67879264-F9245FBE-53A2-4AA9-BFBA-8513B99F7793
instance of	scholarly article
main subject	wds:Q67879264-C2680BED-DBB7-44C1-9C59-913C9A5D8EAD wds:Q67879264-C8D7FD5B-5F3B-4080-8F5C-40302481A2F7
main subject	breast cancer immunotherapy
PubMed ID	wds:Q67879264-784A51F2-ECE0-47DB-BF83-0CD7B78A72DD
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1345869
PubMed ID	1345869
published in	wds:Q67879264-162778EE-7DA3-42FE-BC88-405380DFC25F
published in	The Lancet
issue	wds:Q67879264-18777249-CA92-45D6-91CB-DA2BB2DB6387
volume	wds:Q67879264-7B3F165C-73F9-4214-B8A0-089B4D9A2199
issue	8785
volume	339
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q67879264
is cites work of	Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival Fertility preservation in women with breast cancer Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States) Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy Breast cancer in the eastern province of Saudi Arabia Health-related quality of life in women previously treated for early-stage breast cancer Younger age as a prognostic indicator in breast cancer: a cohort study The molecular profile of luminal B breast cancer The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III. Factors influencing the effect of age on prognosis in breast cancer: population based study Past, present, and future challenges in breast cancer treatment Systemic therapy in breast cancer: efficacy and cost utility Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers Tamoxifen Resistance: Emerging Molecular Targets Contribution of randomised controlled trials to understanding and management of early breast cancer Timing of determining axillary lymph node status when neoadjuvant chemotherapy is used Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India Estrous cycle modulates ovarian carcinoma growth. The plasma DNA concentration as a potential breast cancer screening marker Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats. Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer Antiestrogens--tamoxifen, SERMs and beyond Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer Estradiol increases ER-negative breast cancer metastasis in an experimental model Prognosis and prediction of response in breast cancer: the current role of the main biological markers Prediction of outcome after diagnosis of metachronous contralateral breast cancer Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Abeta Peptide Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status The curability of breast cancer and the treatment of advanced disease. Preclinical models for the evaluation of targeted therapies of metastatic disease A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12) Tamoxifen and ovarian function Dormant Wnt-initiated mammary cancer can participate in reconstituting functional mammary glands Systematic reviews, systematic error and the acquisition of clinical knowledge Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women The role of ovarian ablation in the adjuvant therapy of breast cancer A novel FOXA1/ESR1 interacting pathway: A study of Oncomine™ breast cancer microarrays A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor α gene through GATA-binding protein 3 (GATA3).

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software